Page 9 - norgine-annual-report-2016
P. 9

to improve the understanding of complex diseases and treatments, without compromising their
            independence.

            Support the detection of colorectal cancer
 Dreux
            As a leader in bowel cleansing and colonoscopy, Norgine continued to collaborate with patient
            groups both pan-European and country-specific, to increase the detection of colorectal cancer
            and to help improve patients’ quality of life. Colorectal cancer is the second most common
            cause of cancer-related mortality in the world,  with nearly 1.4 million new cases diagnosed
                                                 3
 Part of Norgine’s strength as a partner lies in
            worldwide and 412,000 people in Europe. 4,5
 its high quality manufacturing and distribution
 facilities in Hengoed, Wales and Dreux,   Advance the understanding of hepatic encephalopathy
 Hengoed
 France and with its external
 contract manufacturing.  We continued to collaborate with patient groups both pan-European and country-specific to
            ensure that hepatic encephalopathy is recognised as a life threatening condition and healthcare
 Norgine has the ability to integrate and
            systems report it like other critical conditions, so that patients can be managed accordingly.
 launch new innovative products very quickly.
            In Europe 200,000  people are affected by hepatic encephalopathy and yet it remains
                           6
            under-diagnosed and under-treated, as many patients and carers are unaware of the signs
 Manufacturing  and symptoms of the disease.

            Improve diagnosis of head and neck cancer
 A number of significant efficiency improvements were introduced
 at Hengoed, which further contributed to a substantial increase in   Norgine started collaborating with patient groups to help standardise the use of sentinel lymph node
 its output of MOVICOL  and MOVIPREP  for Europe but also for   detection, in particular in the field of head and neck cancer. In current practice, patients with early
 ®
 ®
 Norgine’s partners in the US, Japan and the rest of the world.   oral cancer undergo major surgery to remove the lymph nodes to evaluate if the cancer has spread.
            Sentinel lymph node biopsy is a procedure to remove and examine the first nodes where cancer
 Of note, in 2016, for the second time, the Hengoed site was awarded   cells may be present. The standardisation of sentinel lymph node biopsy is important because
 the RoSPA Health and Safety Award in recognition of excellence in   70-80% of patients with head and neck cancer may receive a potentially avoidable major operation
 safety performance.    which they did not need to identify that their lymph nodes were in fact negative. 7


 Norgine introduced new technologies in the Dreux facility in France to
 support the launch of MOVICOL  Ready to Take.
 ®
            Governance

            In 2016, Norgine continued to operate and meet the strict regulatory requirements which govern
 Patient centricity  the pharmaceutical sector. Norgine seeks to always remain compliant with relevant laws,

            regulations and the Norgine Business Code. All Norgine employees are expected to conduct
 Over the years, Norgine has established relationships with key opinion   their duties according to the highest ethical and professional business standards.
 leaders, professional organisations and health services to help
 navigate complex systems and ensure that patients gain access
 to its products.


 Norgine has a long history of actively working with patient groups.   1.  Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe:  Estimates for 40 countries in 2012.
              Eur J Cancer 2013;49:1374-1403.
            2.  Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/
 In 2016, Norgine supported 26 such organisations.   colorectal-cancer-statistics [Accessed 10 May 2017].
            3.  Zavoral M, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
            4.  Amodio P, Del Piccolo F, Pettenò E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic
              patients. J Hepatol. 2001;35(1):37-45.
 Norgine works together with patient groups to achieve common goals   5. Civantos FJ, et al. J Clin Oncol 2010; 28(8): 1395-1400.
            6.  Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the
              American Association for the Study of Liver Diseases. Journal of Hepatology 2014; 61(3):642-659.
 whether these are to shape policies for the benefit of the patients or   7. Civantos FJ, et al. J Clin Oncol 2010; 28(8): 1395-1400.
 7                                                                                                               8
   4   5   6   7   8   9   10   11   12   13   14